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Yaoyao Zhou and Junfeng Zhang*Abstract: Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome is a rare but fatal autosomal recessive
multisystem disorder caused by mutations in the VPS33B or VIPAR gene. The classical presentation of ARC includes
congenital joint contractures, renal tubular dysfunction, and cholestasis. Additional features include ichthyosis, central
nervous system malformation, platelet anomalies, and severe failure to thrive. Diagnosis of ARC syndrome relies on
clinical features, organ biopsy, and mutational analysis. However, no specific treatment currently exists for this
syndrome.
Conclusion: This is an overview of the latest knowledge regarding the genetic features and clinical manifestations of
ARC syndrome. Greater awareness and understanding of this syndrome should allow more timely intervention with
potential for improving long-term outcome.
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Arthrogryposis-renal dysfunction-cholestasis (ARC) syn-
drome (MIM 208085), caused by mutations in the
VPS33B or VIPAR gene, is a rare autosomal recessive mul-
tisystem disorder involving the liver, kidney, skin, and cen-
tral nervous and musculoskeletal systems. In general, case
reports of patients with ARC syndrome are not uncom-
mon in Saudi Arabia and Pakistan, along with several
sporadic cases all around the world. To help clinicians
raise awareness of general clinical picture of ARC syn-
drome, we comprehensively characterize its major clinical
presentation, namely, arthrogryposis, renal dysfunction,
cholestasis, and other associated features.
Though a Leiden Open-Source Variation Database
(LOVD) for ARC has been established by collating all rele-
vant published variants observed in VPS33B and VIPAR,
further analysis is still in urgent need to highlight variants
that have been classified as “pathogenic” worldwide, and
ultimately facilitate accurately counseling and improved
disease management. Thus, we compile a total of 49* Correspondence: jfzhang_dr@163.com
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article, unless otherwise stated.pathogenic VPS33B mutations and 14 pathogenic VIPAR
mutations listed in the ARC-LOVD database to date.
All in all, this article focuses on the latest knowledge re-
garding both clinical and genetic features of ARC syn-
drome and discusses appropriate diagnosis and available
treatment option currently, which gives clinicians an
insight in children at risk of dying from this severe disease.
Moreover, it still stands in need of future attempts at gene
therapy for improvements in managing or even curing
ARC syndrome.Introduction
Arthrogryposis–renal dysfunction–cholestasis (ARC) syn-
drome (MIM 208085) is a rare autosomal recessive dis-
order, which was first recognized in the offspring of a
consanguineous marriage in 1973 [1]. As a fatal multisys-
tem disorder, an affected child would present a series of
clinical features in musculoskeletal systems, kidney, liver,
and central nervous at birth. The characteristic features of
ARC syndrome include arthrogryposis, renal tubular acid-
osis, and neonatal cholestatic jaundice (see Figure 1) [2].
These features are sometimes accompanied by additional
presentations, including ichthyosis (~50%), platelet anom-
alies (~25%), agenesis of the corpus callosum (>20%),
congenital cardiovascular anomalies (~10%), deafness,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 An infant with ARC syndrome showing arthrogryposis
and ichthyotic skin. (Reproduction permission of John Wiley and
Sons License, Number: 3438240519407).
Table 1 Clinical characteristics of patients with ARC
syndrome
Classification Clinical characteristics
Classical clinical feature Arthrogryposis
Renal tubular dysfunction
Neonatal cholestatic jaundice
Additional clinical feature Ichthyosis
Platelet abnormality
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lation dysfunction (see Table 1). The laboratory investiga-
tions and biopsy findings of liver or kidney could
contribute to further evaluation and confirmation of ARC
syndrome. Still, it may be very likely that mild or atypical
symptoms at birth and during the first few weeks would
lead to ignorance, misdiagnose and delayed treatment of
this life-threating disorder. Consequently, the prognosis of
ARC syndrome is so poor that the majority of patients fail
to survive beyond the first year of life [3,4].
The locus of this disorder has been mapped to chromo-
some 5q26.1, and germline mutations have been identified
in vacuolar protein sorting 33 homolog B (VPS33B; MIM
608552) and VPS33B-interacting protein, apical–basolat-
eral polarity regulator (VIPAR; MIM 613401) [3,5,6].
VPS33B encodes a 617-amino-acid protein that is a
homolog of yeast Vps33p, a class C vacuolar protein sort-
ing (vps) protein. Vps33p, along with other class C vps
proteins, comprise the two multiprotein complexes,
homotypic protein sorting (HOPS) and class C core vacu-
ole/endosome tethering (CORVET), to play an essentialrole in intracellular vesicular trafficking pathways [7].
VPS33B is a member of the Sec1/Munc18 family proteins,
which interact with soluble NSF attachment protein
receptors (SNAREs). SNAREs are involved in a variety of
processes—including vesicular exocytosis, synaptic trans-
mission, and general secretion—by facilitating vesicle
targeting and fusion [8]. Once mutations develop in
the human VPS33B gene, the interaction between the
expressed mutant protein and the SNARE protein at the
late endosomal stage may be impeded and lead to abnor-
mal localization or accumulation of plasma proteins in po-
larized cells, providing partial insights into the nature of
the molecular pathophysiology of ARC syndrome.
VPS33B mutations are detectable in approximately
75% of patients with a clinical diagnosis of ARC syn-
drome [9]. Apart from locus heterogeneity or failure to
detect mutation by direct sequencing analysis, another
causative gene of the ARC syndrome, VIPAR (also called
C14ORF133), was subsequently identified by combining
functional and genetic approaches [6]. VIPAR consists of
a golgin A5 domain and shares significant homology
with the C-terminal region of Vps16, which exhibits
pleiotropic effects in polarity and apical membrane pro-
tein restriction through the formation of VPS33B-VIPAR
complexes [10]. The role of VPS33B-VIPAR complexes
are suggested to involve the RAB11A-dependent apical
recycling pathway and transcriptional regulation of ad-
herent proteins such as E-cadherin, which ensures nor-
mal cellular structure with apical basolateral polarity [6].
It is noteworthy that further research has confirmed the
role of epidermal growth factor (EGF) stimulation in
the interactions between SPE-39—the Caenorhabditis
elegans ortholog of VIPAR—and Vps33B by tyrosine
phosphorylation and ubiquitination of SPE-39 [11-13].
Alternatively, the apical membrane protein was observed
to be misrecruited to basolateral membranes and into
the late endosomes and lysosomes in knockdown/
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quently, abnormal organelle biogenesis may hinder the
generation and maintenance of tissue structures, such as
bile ducts and renal tubules, ultimately resulting in cho-
lestasis and abnormal urine. These proteins are found at
various locations throughout the body, including the
skeletal muscles, kidneys, liver, skin, heart, lungs, and
brain, which explains the multisystemic symptoms that
are characteristic of the ARC clinical phenotype [5,6,15].
Clinical presentation of ARC syndrome
Arthrogryposis
Arthrogryposis is a primary symptom of ARC syndrome
and presents with a spectrum of manifestations, including
muscle atrophy, radial deviation of the wrist, dislocation of
both hip joints, flexion contracture of the knee joints, and
calcaneovalgus [2]. Musculoskeletal abnormalities observed
during the first few weeks of life are not generally evident—
or perhaps they are simply absent or atypical in certain in-
stances of VPS33B mutations, such as 971delA/K324fs
[16,17]. The pathogenesis characteristic of ARC syndrome
is primarily degeneration of anterior motor neurons,
whereas the severity of arthrogryposis may be traced to pla-
cental insufficiency during pregnancy with oligohydramnios
in the mother and growth restriction of the fetus. In
addition, osteopenia and pathological fractures in ARC syn-
drome are related to impaired reabsorption linked to renal
tubular and secondary hyperparathyroidism. Nevertheless,
fractures and osteopenia are due to decreased or absent
fetal movements in other kind of congenital arthrogryposis
such as Bruck syndrome [18]. In case of osteopenia and
fractures with arthrogryposis at birth, it is also suggested
that ARC syndrome should be included in the differential
diagnosis. Especial attention should be paid to the patients
associated with other clinical features, such as renal tubular
dysfunction, and cholestasis.
Renal tubular dysfunction
Renal tubular dysfunction manifests in the form of Fan-
coni syndrome, with symptoms including renal tubular
acidosis, nephrogenic diabetes insipidus, glucosuria, ami-
noaciduria, and phosphaturia [19,20]. During episodes of
intercurrent illness, renal tubular acidosis may be not-
ably exacerbated, which is symptomatic of renal tubular
calcification and degeneration. Renal ultrasonography
may be suggestive of nephrocalcinosis or a small dys-
plastic kidney, accompanied by inflammatory reaction of
the renal interstitium and focus, sclerosis of some glom-
eruli, and tubular distortion and degeneration, per the
results of renal biopsy [3,16].
Neonatal cholestatic jaundice
The third primary feature of ARC syndrome is neonatal
cholestatic jaundice, concurrent with hepatomegaly, whichis the most common characteristic of ARC syndrome. The
presentation of neonatal cholestatic jaundice in ARC syn-
drome is distinct from the other clinical presentations of
neonatal cholestatic jaundice; patients who have ARC syn-
drome and develop neonatal cholestatic jaundice typically
present with no biliary obstruction, have consistently low
γ-glutamyl transpeptidase (γGT) levels, and have normal
or slightly elevated aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels, although they have
jaundice and liver cell dysfunction [17]. Indeed, it is well
accepted that low GGT cholestasis is a differential feature
of ARC syndrome. It is even recommended that patients
with low-GGT conjugated hyperbilirubinemia associated
with ichthyosis, deafness, platelet dysfunction and central
nervous system malformation should be related to VPS33B
disease [17].Furthermore, liver biopsies suggest signs of
paucity of bile ducts, giant cell transformation, bile plug or
lipofuscin deposition, and portal fibrosis in these cases,
which could exclude biliary atresia specifically [3,21,22].
Other associated features of ARC syndrome
Additional clinical symptoms of ARC syndrome princi-
pally include ichthyosis, abnormal platelet count and func-
tion, secondary infection, and cardiovascular anomalies
[3,9]. Most patients are affected with ichthyosis (a hetero-
geneous family of skin disorders) stemming from defects
in the SNARE protein, which participates in secretion and
function in epidermal cohesion and waterproofing of la-
mellar granules [23,24]. Despite the fact that abnormal la-
mellar granule secretion exist in both ARC syndrome and
cerebral dysgenesis–neuropathy–ichthyosis–keratoderma
(CEDNIK) syndrome, lamellar granule internal structure
is normal in ARC syndrome while it is abnormal in CED-
NIK syndrome. An additional cause of ichthyosis in ARC
syndrome is the lack of absorption of free fatty acids,
which are critical for epidermal differentiation [25]. Fur-
thermore, skin biopsy may indicate the presence of mild
hyperkeratosis without parakeratosis. Self-limiting intra-
abdominal hemorrhage often occurs in patients with
ARC, in the absence of abnormal platelet morphology;
therefore, normal routine platelet analysis cannot assess
the risk of bleeding in ARC syndrome [9]. Despite the in-
creased number of β-granules, similar to Grey platelet
syndrome, platelets from patients with ARC syndrome de-
velop abnormal biosynthesis and function of α-granules,
which are essential for platelet aggregation, thrombogen-
esis, inflammation, and tumorigenesis [26,27]. Studies
have demonstrated that a VPS33B-VPS16B complex par-
ticipates in α-granule formation, since this complex was
tracked with transport vesicles destined toward the devel-
opment of mature α-granules [28,29]. Moreover, patients
with ARC syndrome primarily have recurrent episodes of
secondary infection coupled with hyperpyrexia and chronic
diarrhea, although their immunological profiles are found
Table 2 Pathogenic VPS33B mutations listed in the ARC-LOVD database
Database ID Exon DNA change Status Protein change Ethnicity Reference
VPS33B_00235 1-23 c.(?_-354)_(*431 + d127_?)del Het p.(0?) Hispanic [14]
VPS33B_00232 △4 c.240-577_290-156del Het p.(Leu81Serfs*5) South American [14]
VPS33B_00221 1 c.67C > T Het p.(Arg23*) - [14]
VPS33B_00001 1 c.89 T > C Hom p.(Leu30Pro) Pakistani [3]
VPS33B_00223 1i c.97-2A > C Hom p.(?) - [14]
VPS33B_00002 2 c.151C > T Het p.(Arg51*) French [8]
VPS33B_00011 2i c.177 + 1G > A Hom p.(?) Italian [3]
VPS33B_00231 2i c.178-2A > C Hom p.(?) Turkish [14]
VPS33B_00224 2i c.178-1G > C Hom p.(?) Pakistani [14]
VPS33B_00233 3i c.240-1G > C Hom p.(?) - [14]
VPS33B_00003 4 c.277C > T Het p.(Arg93*) South American [8]
VPS33B_00004 5 c.319C > T Het p.(Arg107*) Scottish [8]
VPS33B_00005 5 c.352C > T Hom p.(Gln118*) Turkish [7]
VPS33B_00023 5 c.350del Hom p.(Pro117Leufs*20) Saudi Arabia [3]
VPS33B_00024 6 c.369_370del Het p.(Cys123*) South American [8]
VPS33B_00013 6i c.403 + 1G > T Het p.(?) Scottish [8]
VPS33B_00012 6i c.403 + 1G > A Het p.(?) Israel [3]
VPS33B_00014 6i c.403 + 2 T > A Het p.(?) Korean [7]
VPS33B_00025 7 c.436_445del Het p.(Leu146Metfs*5) French [8]
VPS33B_00015 7i c.498 + 1G > A Het p.(?) Swedish [4]
VPS33B_00026 8 c.558_559del Het p.(Tyr187Trpfs*18) Italian [8]
VPS33B_00006 9 c.661C > T Het p.(Arg221*) Korean [21]
VPS33B_00016 9i c.701-1G > C Hom p.(?) Israel [25]
VPS33B_00017 9i c.700 + 1G > A Het p.(?) Saudi Arabia [15]
VPS33B_00225 10 c.711del Het p.(Phe237Leufs*2) Pakistani [14]
VPS33B_00007 10 c.728C > T Het p.(Ser243Phe) Korean [7]
VPS33B_00027 10 c.740_741del Het p.(Tyr247*) Korean [7]
VPS33B_00226 11i c.853-3C > G Hom p.(?) Turkish [14]
VPS33B_00019 11i c.853-2A > G Het p.(?) Portuguese [3]
VPS33B_00018 12i c.940-1G > A Het p.(?) French [8]
VPS33B_00028 13 c.971del Hom p.(Lys324Argfs*11 Pakistani [17]
VPS33B_00227 13i c.1030 + 5G > T Hom p.(?) Saudi Arabia [14]
VPS33B_00029 16 c.1208del Het p.(Leu403Cysfs*8) Tahitian [8]
VPS33B_00230 16i c.1225 + 5G > C Het p.(?) South American [14]
VPS33B_00033 17 c.1235_1236delCCinsG Hom p.(Pro412Argfs*7) Polish [7]
VPS33B_00229 17 c.1261_1262del Het p.(Gln421Valfs*8) South American [14]
VPS33B_00008 18 c.1312C > T Hom p.(Arg438*) Pakistani [3]
VPS33B_00008 18 c.1312C > T Het p.(Arg438*) Saudi Arabia [15]
VPS33B_00008 18 c.1312C > T Het p.(Arg438*) Pakistani [14]
VPS33B_00219 18i c.1406-2A > G Hom p.(?) Saudi Arabia [3]
VPS33B_00220 18i c.1406-1G > C Hom p.(?) Turkish [8]
VPS33B_00228 20 c.1498G > T Hom p.(Glu500*) Hispanic [14]
VPS33B_00030 20 c.1509dupG Het p.(Lys504Glufs*23) Korean [7,21]
VPS33B_00009 20 c.1519C > T Het/Hom p.(Arg507*) Portuguese [3,18]
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Table 2 Pathogenic VPS33B mutations listed in the ARC-LOVD database (Continued)
VPS33B_00218 20 c.1519C > T Het p.(Arg507*) Korean [21]
VPS33B_00031 20 c.1576_1577insT Hom p.(Glu526Valfs*13) Polish [7]
VPS33B_00010 21 c.1594C > T Hom p.(Arg532*) Pakistani [3]
VPS33B_00234 21i c.1657 + 1G > A Hom p.(?) Italian [14]
VPS33B_00032 23 c.1803dupA Het p.(Val602Serfs*13) Korean [7]
Del, deletion; Fs, frameshift; i, intron; ∗, stop; △, whole exon deletion; Het, heterozygous; Hom, homozygous.
p.(?), effect of the variant on the protein is unknown.
p.(0?), no protein product is predicted.
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strated that a profound defect in phagosome-lysosome fu-
sion caused by Vps16B/Vps33B dysfunction may render
patients with ARC syndrome increasingly sensitive to infec-
tions by nonpathogenic microbes [30]. Interestingly, bacter-
ial endocarditis subject to recurrent infection has also been
reported to originate from congenital cardiovascular anom-
alies, other than the structural abnormalities caused by de-
fects in vesicular trafficking [3].
Genetic background
To gain an insight into worldwide genetic epidemiology
and provide easy access to updated resources for
researchers and clinicians, a Leiden Open-Source Vari-
ation Database (LOVD) for ARC (https://grenada.lumc.
nl/LOVD2/ARC) was established in 2011 by collating
all relevant published variants observed in VPS33B and
VIPAR [31]. As for March 2014, this online locus-
specific ARC database has compiled a total of 299
unique variants in VPS33B and 34 unique variants in
VIPAR, of which sequence mutations are basically
classified as “pathogenic,” “probably pathogenic,” “noTable 3 Pathogenic VIPAR mutations listed in ARC-LOVD data
Database ID Exon DNA change status
VIPAR_00001 1 c.2 T > G Hom
VIPAR_00021 6 c.463_464del Het
VIPAR_00022 6 c.484C > T Het
VIPAR_00002 7 c.535C > T Hom
VIPAR_00023 9 c.638 T > C Het
VIPAR_00003 9 c.658C > T Hom
VIPAR_00003 9 c.658C > T Het
VIPAR_00007 10 c.749_753del Hom
VIPAR_00004 11 c.808C > T Hom
VIPAR_00020 11i c.837-1G > T Hom
VIPAR_00005 12 c.871C > T Het
VIPAR_00019 13 c.1021 T > C Hom
VIPAR_00006 17 c.1273C > T Hom
Del, deletion; Fs, frameshift; i, intron; ∗, stop; △, whole exon deletion; Het, heterozyg
p.(?), effect of the variant on the protein is unknown.
p.(0?), no protein product is predicted.known pathogenicity,” “probably no pathogenicity,” and
“effect unknown,” according to their projected effect on
the protein and the clinical phenotype. To date, the
database includes 49 published variants in VPS33B and
14 published variants in VIPAR worldwide that have
been classified as “pathogenic.” Regarding VPS33B,
most identified variants were substitutions (n = 34; 19
splice site, 13 nonsense, and two missense mutations),
apart from deletions (n = 11), duplications (n = 2), inser-
tions (n = 1), and indels (n = 1). It is noteworthy that
three variants were prominent on account of their
relative prevalence: c.403 + 2 T > A, c.1312C > T, and
c.1519C > T (see Table 2). Most “pathogenic” variants in
VIPAR are substitutions (n = 11; 8 nonsense, two mis-
sense, and one splice site mutation). Additionally, two
deletions were present, of which two recurrent variants
existed: c.658C > T and c.808C > T (see Table 3). This in-
formation is available in the ARC–LOVD database to
inform clinicians and patient families on current prog-
noses, advances, and clinical course of ARC pathogen-
esis, ultimately contributing to accurately counseling
and improved disease management.base
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In general, case reports of patients with ARC syndrome
are not uncommon in Saudi Arabia and Pakistan, where
rates of consanguinity are high, whereas several sporadic
case studies have been reported in Turkey, North Africa,
Italy, Portugal, and Asia [5,31-34]. Despite these reports,
the prevalence of ARC syndrome has not been accur-
ately defined and is subject to potential underestimation
because of lack of a broad clinical picture and of early
recognition of this rare disease. It is worth mentioning
that the relative incidence rate ratio of ARC was sug-
gested to be 1/7 that of biliary atresia in 90 patients with
neonatal cholestasis (95% CI 0.33 ~ 0.06) [21,22,35].
ARC syndrome is a life-threatening autosomal recessive
multisystem disorder, and its early diagnosis is of vital
importance for the development of an appropriate thera-
peutic regimen. Currently, clinical diagnosis of ARC syn-
drome consists of identifying the triad conditions of
arthrogryposis, renal tubular acidosis, and neonatal chole-
static jaundice with low γGT activity, combined with
pathologic confirmation. However, the majority of patients
are vulnerable to coagulation defects; in other words, kid-
ney or liver biopsies result in a risk of fatal bleeding
(>50%). Still, similar clinical and laboratory findings could
be observed both in ARC syndrome and progressive famil-
ial intrahepatic cholestasis. Therefore, clinical presenta-
tions along with VPS33B and VIPAR sequencing analyses
constitute an apparently safer diagnostic procedure. Cur-
rently, there are limitations in mutational analysis, such as
the long duration required for analysis and the potential
for false negatives, analysis of VPS33B protein expression
in skin fibroblasts and platelet morphology in peripheral
blood smears are two alternative techniques that have
been proposed as valuable tools for diagnostic screening
examinations [9,36].
Treatment options and prognosis
No specific treatment for ARC syndrome currently ex-
ists; rather, supportive care—including fluid infusion,
anti-infection, supplement with ursodeoxycholic acid,
fat-soluble vitamins, calcium glubionate, L-thyroxine
and phosphate—is administered to patients for improv-
ing the quality of life. Nevertheless, some patients with
joint contractures, congenital hip dislocation, and verti-
cal talus are in need of immediate orthopedic interven-
tion due to delayed diagnosis. Nevertheless, aggressive
orthopedic management is still not recommended, since
poor general status and low survival rates may affect the
outcome of the surgery [37]. In cases of ARC syndrome
that failed to respond to medical therapy, it is also ad-
visable to consider liver transplant to ameliorate severe
cholestasis and intractable pruritus. It is reported that an
Iranian boy underwent a liver transplant have made a re-
covery. Specifically, the pruritus immediately improvedafter the surgery, and his scaly skin was also normal in
6 months. Moreover, the patient stayed in good condition
without any complications or rejection during more than
5 years’ follow-up [38].
As a lethal multisystem disorder, prognosis of ARC syn-
drome is particularly poor. Most patients succumb within
the first year of life after developing recurrent infection,
severe hydropenia, acidosis, or internal hemorrhaging, ex-
cept for a few patients who have ARC syndrome but retain
partial function of VPS33B [22].
Conclusion
No specific treatment currently exists for ARC syndrome.
Comprehensive analysis of family history, classical clinical
presentations, biopsy of the liver or kidney, and/or genetic
mutational analysis may not only facilitate accurate diag-
nosis and the development of appropriately tailored treat-
ment at an early stage but also provide genetic counseling
and prenatal or preimplantation genetic diagnosis for the
affected families. With the continued progress of molecu-
lar genetics and medical technologies, future attempts at
gene therapy may yield improvements in managing or
even curing ARC syndrome.
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